Literature DB >> 18656466

Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats.

Khalid Benamar1, Ellen B Geller, Martin W Adler.   

Abstract

The present data provide the first in vivo evidence that the proinflammatory chemokine, Regulated on Activation Normal T cell Expressed and Secreted (RANTES/CCL5) microinjected directly into the periaqueductal grey in rats, a brain region critical to the processing of pain signals, and a primary site of action of many analgesic compounds, induced hyperalgesia. Pretreatment with antibodies against RANTES/CCL5 prevented the hyperalgesic response, indicating that RANTES/CCL5 is able to interfere with the control of hyperalgesia at the level of the periaqueductal grey and suggesting that chemokine blockers could have analgesic properties.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656466     DOI: 10.1016/j.ejphar.2008.07.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Painful pathways induced by TLR stimulation of dorsal root ganglion neurons.

Authors:  Jia Qi; Krisztina Buzas; Huiting Fan; Jeffrey I Cohen; Kening Wang; Erik Mont; Dennis Klinman; Joost J Oppenheim; O M Zack Howard
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

2.  CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung.

Authors:  Cyrille Mionnet; Vanessa Buatois; Akira Kanda; Valerie Milcent; Sebastien Fleury; David Lair; Marie Langelot; Yannick Lacoeuille; Edith Hessel; Robert Coffman; Antoine Magnan; David Dombrowicz; Nicolas Glaichenhaus; Valerie Julia
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

3.  Calcitonin gene-related peptide contributes to peripheral nerve injury-induced mechanical hypersensitivity through CCL5 and p38 pathways.

Authors:  Jennifer T Malon; Ling Cao
Journal:  J Neuroimmunol       Date:  2016-05-06       Impact factor: 3.478

4.  Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management.

Authors:  Toby K Eisenstein; Xiaohong Chen; Saadet Inan; Joseph J Meissler; Christopher S Tallarida; Ellen B Geller; Scott M Rawls; Alan Cowan; Martin W Adler
Journal:  Mil Med       Date:  2020-01-07       Impact factor: 1.437

5.  Potentiation of morphine antinociception and inhibition of diabetic neuropathic pain by the multi-chemokine receptor antagonist peptide RAP-103.

Authors:  Michael R Ruff; Saadet Inan; Xiang Qun Shi; Joseph J Meissler; Martin W Adler; Toby K Eisenstein; Ji Zhang
Journal:  Life Sci       Date:  2022-07-09       Impact factor: 6.780

6.  Contribution of G Protein-Coupled Receptor 55 to Periaqueductal Gray-Mediated Antinociception in the Inflammatory Pain.

Authors:  Henry Blanton; Sabiha Armin; Steven Muenster; Mary Abood; Khalid Benamar
Journal:  Cannabis Cannabinoid Res       Date:  2022-05-24

7.  Coadministration of Chemokine Receptor Antagonists with Morphine Potentiates Morphine's Analgesic Effect on Incisional Pain in Rats.

Authors:  Saadet Inan; Toby K Eisenstein; Mia N Watson; Menahem Doura; Joseph J Meissler; Christopher S Tallarida; Xiaohong Chen; Ellen B Geller; Scott M Rawls; Alan Cowan; Martin W Adler
Journal:  J Pharmacol Exp Ther       Date:  2018-09-24       Impact factor: 4.030

Review 8.  Inflaming the brain: CRPS a model disease to understand neuroimmune interactions in chronic pain.

Authors:  C Linnman; L Becerra; D Borsook
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-29       Impact factor: 4.147

9.  Inhibition of NADPH oxidase within midbrain periaqueductal gray decreases pain sensitivity in Parkinson's disease via GABAergic signaling pathway.

Authors:  W Zhang; L Sun; X Yang; R Wang; H Wang
Journal:  Physiol Res       Date:  2020-06-25       Impact factor: 1.881

Review 10.  Chemokines, cytokines and substance use disorders.

Authors:  Olivia C Ahearn; Mia N Watson; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2021-01-08       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.